Results 11 to 20 of about 45,910 (249)

Pemphigoid. Bullous and cicatricial.

Dermatologic Clinics, 1990
Bullous pemphigoid is a blistering disease of the elderly that often is self-limited. It is apparently caused by autoantibodies against antigens of the basal cell hemidesmosome. There is apparently more than one antigen, but the most significant has a molecular weight of about 230 kD and the second most frequently detected antigen has a lower molecular

semanticscholar   +4 more sources

Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases [PDF]

, 2018
Introduction: Rituximab (RTX) is a monoclonal antibody targeting CD20, a transmembrane protein expressed on B cells, causing B cell depletion. RTX has shown great efficacy in studies of pemphigus vulgaris, but data of pemphigoid diseases are limited ...
Euverman, H. Ilona, Horvath, Barbara, Jonkman, Marcel F., Lamberts, Aniek, Terra, Jorrit B.   +4 more
core   +17 more sources

Bullous pemphigoid [PDF]

Anais Brasileiros de Dermatologia, 2019
Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects elderly individuals. Increase in incidence rates in the past decades has been attributed to population aging, drug-induced cases and improvement in the diagnosis of the nonbullous presentations of the disease. A dysregulated T cell immune response and synthesis of IgG
Denise Miyamoto, Claudia Giuli Santi, Valéria Aoki, Celina Wakisaka Maruta   +3 more
openaire   +5 more sources

Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid

Acta Dermato-Venereologica, 2021
Massive recruitment of eosinophils into the dermis is a hallmark of bullous pemphigoid pathogenesis. Identifying the chemoattractant(s) guiding eosinophils into the skin in bullous pemphigoid is a prerequisite to thera­peutic targeting of eosinophil ...
Jasper Pruessmann, Wiebke Pruessmann, Maike M. Holtsche, Beke Linnemann, Christoph M. Hammers, Nina van Beek, Detlef Zillikens, Enno Schmidt, Christian D. Sadik   +8 more
doaj   +1 more source

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients

Case Reports in Dermatology, 2022
Bullous pemphigoid is the most common acquired bullous disease with an autoimmune basis and a tendency to involve mostly old people. By rising incidence of diabetes all over the world, consumption of antidiabetes medications has also increased.
Kamran Balighi, Sama Heidari, Mohammadreza Kavyani, Kambiz Kamyab Hesari, Nasim Tootoonchi   +4 more
doaj   +1 more source

Interventions for bullous pemphigoid [PDF]

Cochrane Database of Systematic Reviews, 2003
Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Oral steroids are the standard treatment.This is an update of the review published in 2005.To assess treatments for bullous pemphigoid.In August 2010 we updated our searches of the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled ...
Khumalo, N., Kirtschig, G., Middleton, P., Hollis, S., Wojnarowska, F., Murrell, D.   +5 more
openaire   +9 more sources

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

Journal of the European Academy of Dermatology and Venereology, 2022
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions.
L. Borradori, N. van Beek, C. Feliciani, B. Tedbirt, E. Antiga, R. Bergman, B. Böckle, M. Caproni, F. Caux, N. S. Chandran, G. Cianchini, M. Daneshpazhooh, D. De, D. Didona, G. Di Zenzo, M. Dmochowski, K. Drenovska, J. Ehrchen, M. Goebeler, R. Groves, C. Günther, B. Horváth, M. Hertl, S. Hofmann, D. Ioannides, B. Itzlinger-Monshi, J. Jedlickova, C. Kowalewski, K. Kridin, Y. L. Lim, B. Marinović, A. Marzano, J. Mascaro, J. Meijer, D. Murrell, K. Patsatsi, C. Pincelli, C. Prost, K. Rappersberger, M. Sárdy, J. Setterfield, M. Shahid, E. Sprecher, K. Tasanen, S. Uzun, S. Vassileva, K. Vestergaard, A. Vorobyev, I. Vujic, G. Wang, K. Wozniak, S. Yaylı, G. Zambruno, D. Zillikens, E. Schmidt, P. Joly   +55 more
semanticscholar   +1 more source

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review

Frontiers in Immunology, 2022
Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. First-line treatment of systemic corticosteroids may cause serious adverse events.
Peng Cao, Wenjing Xu, Litao Zhang
semanticscholar   +1 more source

Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.

JAMA dermatology, 2022
Importance Bullous pemphigoid is a difficult-to-treat autoimmune blistering skin disease that predominantly affects older adults and is associated with an increased mortality rate. Objective To examine the safety and therapeutic potential of nomacopan,
C. Sadik, H. Rashid, C. Hammers, G. Diercks, A. Weidinger, S. Beissert, F. Schauer, James Fettiplace, D. Thaçi, Y. Ngai, M. Nunn, D. Zillikens, B. Horváth   +12 more
semanticscholar   +1 more source

Risk of Serious Infections in Patients with Bullous Pemphigoid: A Population-based Cohort Study

Acta Dermato-Venereologica, 2023
Patients with bullous pemphigoid are susceptible to serious infections, which are the leading cause of death in these patients. The aims of this population-based cohort study were to investigate the incidence and spectrum of serious infections in ...
Tsung-Hsien Chang, Chun-Ying Wu, Yun-Ting Chang, Ying-Syuan Lyu, Chen-Yi Wu   +4 more
doaj   +1 more source